代表论著 |
Yonglei Zhang,Xiaomin Xie, Xueyuan Wang, Tiantian Wen, Chi Zhao, Hailong Liu, Bo Zhao*,Yongqiang Zhu*.Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors.Bioorg. Med. Chem.2021, 38, 116114.
Chenxi Gu, Yonglei Zhang, Xiaomin Xie, Xueyuan Wang, Bo Zhao*,Yongqiang Zhu*.Pharmacophore modeling, atom-based 3D-QSAR and molecular docking studies on N-benzylpyrimidin-4-amine derivatives as VCP/p97 inhibitors.Med. Chem. Res.2020, 29, 727–737.
Meng Lei*, Hang Miao, Xueyuan Wang, Wen Zhang, Chengjian Zhu, Xiaqiang Lu,Jian Shen, Yanru Qin, Haoyang Zhang, Sijia Sha,Yongqiang Zhu*. Trifluoromethyl aryl sulfonates (TFMS): an applicabletrifluoromethoxylation reagent.Tetrahedron Lett.2019, 60, 1389-1392.
Meng Lei*, Haoyang Zhang, Hang Miao, Xiao Du, Hui Zhou, Jia Wang, Xueyuan Wang, Huayun Feng, Jingmiao Shi, Zhaogang Liu, Jian Shen,Yongqiang Zhu*. Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors.Bioorgan. Med. Chem.2019, 27, 4151-4162.
Meng Lei, Sijia Sha, Xueyuan Wang, Jia Wang, Xiao Du*, Hang Miao, Hui Zhou, Enhe Bai, Jingmiao Shi,Yongqiang Zhu*. Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer.RSC Adv.,2019, 9, 5512–5520.
Xueyuan Wang, Enhe Bai, Hui Zhou, Sijia Sha, Hang Miao, Yanru Qin, Zhaogang Liu, Jia Wang, Haoyang Zhang, Meng Lei*, Jia Liu, Ou Hai,Yongqiang Zhu*. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.Bioorgan. Med. Chem.2019,27, 533-544.
Meng Lei,*Huayun Feng, Enhe Bai, Hui Zhou, Jia Wang, Yanru Qin, Haoyang Zhang, Xueyuan Wang, Zhaogang Liu, Ou Hai, Jia Liu,Yongqiang Zhu*.Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multipe myeloma and triple-negative breast cancer.Org. Biomol. Chem.2019, 17, 683-691.
Meng Lei, Guanglan Ma, Sijia Sha, Xueyuan Wang, Haiting Feng,Yongqiang Zhu*, Xiao Du*. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance.Drug Deliv.2019, 26, 262-272.
|